Who are TILD's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Omvoh, Skyrizi, Sunpg 1622, ILUMYA, OMVOH, Injections of tildrakizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tild.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

TILD — Competitive Intelligence Brief

TILD (TILD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed Interleukin-23 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

TILD (TILD) — Sun Pharmaceutical Industries Limited. Tild is a small molecule that works by interacting with a specific target in the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TILD TARGET	TILD	Sun Pharmaceutical Industries Limited	marketed		Interleukin-23
Omvoh	MIRIKIZUMAB	Eli Lilly Nederland B.V.	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha	2023-01-01
Skyrizi	RISANKIZUMAB	AbbVie	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha	2019-01-01
Sunpg 1622	TILDRAKIZUMAB	Sun Pharma Global	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23	2018-01-01
ILUMYA	TILDRAKIZUMAB-ASMN	SUN PHARMA GLOBAL	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23
OMVOH	MIRIKIZUMAB-MRKZ	ELI LILLY AND CO	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha
Injections of tildrakizumab	Injections of tildrakizumab	Sun Pharmaceutical Industries Limited	marketed	IL-23 inhibitor monoclonal antibody	IL-23 (interleukin-23), p19 subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TILD — Competitive Intelligence Brief. https://druglandscape.com/ci/tild. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab